Premium
Therapy of adult acute leukemia with daunorubicin and L‐asparaginase
Author(s) -
Bodey Gerald P.,
Hewlett James S.,
Coltman Charles A.,
Rodriguez Victorio,
Freireich Emil J.
Publication year - 1974
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197403)33:3<626::aid-cncr2820330306>3.0.co;2-5
Subject(s) - medicine , daunorubicin , leukemia , complete remission , acute lymphocytic leukemia , gastroenterology , asparaginase , acute leukemia , chemotherapy , surgery , lymphoblastic leukemia
Fifty‐four adults with acute leukemia resistant to other therapies received treatment with Daunorubicin and L‐asparaginase. Seventeen (31%) achieved complete remission. The complete remission rate was higher among the 31 patients receiving simultaneous therapy than among the 23 patients receiving sequential therapy (42% vs. 17%). Patients with acute lymphocytic leukemia had a higher remission rate than patients with acute myelogenous leukemia (38% vs. 20%). The median duration of complete remission was only 12 weeks, and the median duration of survival for responders was 30 weeks.